2009-01-12 11:24:03 -

EKR Therapeutics, Inc., a specialty pharmaceutical company focused on providing novel products for the acute-care hospital setting, today announced that Howard Weisman, the Company's Chairman and Chief Executive Officer, has been invited to present at the 27th Annual J.P. Morgan Healthcare Conference.


The Conference will take place from Jan 12, 2009 - Jan 15, 2009 at the Westin

St. Francis Hotel located at 335 Powell Street in San Francisco. Weisman will present an overview of EKR and its core hospital products including DepoDur® and recently approved Cardene® I.V. Ready-to-Use premixed intravenous bags. The EKR presentation, which will also include a preliminary review of 2008 financial results, is scheduled for Tuesday, January 13 at 3:30 pm PT.


About EKR Therapeutics


EKR Therapeutics is a privately held specialty pharmaceutical company focused on identifying, fostering and targeting the growth of novel acute-care hospital products to improve outcomes and patient quality of life. The Company's growing portfolio of products include: Cardene® I.V. (nicardipine hydrochloride) premixed injection, Retavase® (reteplase recombinant), DepoDur® (morphine sulfate extended-release liposomal injection), and Gelclair® (bioadherent oral gel). For additional information about EKR visit www.ekrtx.com. Full prescribing and other information about Cardene I.V. and DepoDur are available, respectively, at www.cardeneiv.com and www.depodur.com.








EKR Therapeutics

Stuart Z. Levine, Ph.D., 877-435-2524

Director, Corporate Communications/IR

s.levine@ekrtx.com